European law changes mean drugmakers may have to grapple with generic competition sooner
European regulators will soon sign in a new raft of laws that could make drugmakers jump through more hoops to delay generic and biosimilar competition. And companies developing rare disease and orphan drugs are likely ...
⚠️ 风险分析 中
摘要：欧洲新法规将加速仿制药竞争，可能影响原研药企市场独占期。
影响：对在欧洲市场运营的中国及跨国药企，可能缩短创新药盈利窗口，增加市场准入和定价压力。
建议：评估法规对产品管线的影响，调整市场策略，加强仿制药竞争应对准备。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.